Can Your Content Get You in Hot Water with the FDA?

Are you creating FDA-compliant content when discussing the benefits of CBD and CBD products? If you find yourself writing, saying, or communicating in any way “CBD can treat…”, or any similar sentiment -- stop now, or you may find yourself in hot water.

Last month, CBD producer Curaleaf Inc. was issued a letter by the U.S. Food and Drug Administration (FDA) for selling unapproved products with unsubstantiated claims that its product could treat various medical conditions including cancer and Alzheimer’s Disease.

Claims found in Curaleaf’s materials included: “CBD has been demonstrated to have properties that counteract the growth of [and/or] spread of cancer,” and “CBD can also be used in conjunction with opioid medications, and a number of studies have demonstrated that CBD can in fact reduce the severity of opioid-related withdrawal and lessen the buildup of tolerance,” and ““CBD has been linked to the effective treatment of Alzheimer’s disease…”

All these statements are problematic, and illegal, when it comes to talking about CBD in the United States. WHY? Only ONE product containing CBD has been approved by the FDA. The FDA approval process ensures that drugs on the market are safe and effective for their intended therapeutic uses.

FDA approval requires a substantial drug approval process that also reviews and approves manufacturing processes. Without FDA approval, there is no dosing guidelines, guarantee that the products won’t interact with other FDA-approved drugs, or provide side effects or safety concerns. Unsubstantiated claims associated with CBD products may lead consumers to put off getting important medical care, such as proper diagnosis, treatment and supportive care. 

It’s important to be an educated consumer about CBD in the USA, in the new reality of legal hemp-based CBD. More importantly, you MUST, as a CBD company talk about CBD in a way that does not get your brand in hot water with the FDA. CannaWrite can help! We specialize in providing content that will avoid FDA detection, while responsibly educating the consumer about CBD. Connect with us today!